| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 1/2a data readout example | Phase 1/2a | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders | ||
phase 1/2a data readout example | Phase 1/2a | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders | ||
phase 1/2a data readout example | Phase 1/2a | — | Subscribe to access the data. | Small Molecules | Psychiatric Disorders |
Recent Updates
Recently added Catalysts
Clearmind Medicine Inc.$2.03
-0.04 (-1.93%)
D 21Pipeline Score Richly Valued Biotech · Clinical
Market Cap
1.37 M
EPS
-24.14
P/E Ratio
-0.03 $
Value Trade
513.94 K
17.95 %
Week
-17.37 %
1 Month
21.05 %
3 Month
-27.37 %
6 Month
-99.78 %
5 Year
-99.78 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
97.61 K
52 Week Range
0.59 - 52.40
% held by Insiders
0.13 %
% held by Institutions
5.67 %
Enterprise Value
-8.96 M
Total Shares
158.04 K
Short %
129.84 %
Float Shares
156.62 K
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Clearmind Medicine Inc.
285Total events
3Upcoming
42Tier-1 (high impact)
2021 – 2026Coverage
Upcoming catalysts 3
Event history 282
Jul 10, 2026
●Other Regulator MilestoneEx-US Regulatory
Clearmind submitted formal response to HHS RFI about MEAI's potential for addiction treatment
addiction treatmentsource ↗
Jul 7, 2026
▲Preclinical PoCMEAIPreclinical
Successful formulation feasibility study for intranasal delivery of MEAI
alcohol use disordersource ↗
Jun 29, 2026
▲Patent GrantedMEAIIP / Competition
US Patent No. 12,357,590 'BINGE BEHAVIOR REGULATORS' granted by USPTO
binge behaviors (excessive drinking, eating, compulsive disorders)source ↗
Jun 29, 2026
▲Patent GrantedMEAIIP / Competition
U.S. Patent No. 12,357,590 granted for MEAI and related compounds
binge behaviorssource ↗
Jun 22, 2026
▲Enrollment CompleteCMND-100Trial
Completed treatment for all 24 participants in Part A of Phase I/II trial
Alcohol Use Disordersource ↗
Jun 18, 2026
▲Patent GrantedMEAIIP / Competition
U.S. Patent No. 12,350,242 granted for MEAI as binge behavior regulator
binge behaviors (excessive drinking, eating, gambling)source ↗
Jun 16, 2026
▲Enrollment CompleteCMND-100Trial
Completed dosing for all 24 participants in Cohorts 1-4 of Part A
Alcohol Use Disordersource ↗
Jun 15, 2026
Jun 12, 2026
▼Equity OfferingCorporate
Additional convertible note purchase of $1,000,000 principal amount
Jun 10, 2026
◆Oral PresentationCMND-100Presentation
Inside MEAI Webinar: New Insights from CMND-100 Psychedelic Clinical Trial
Alcohol Use Disordersource ↗
May 29, 2026
▲Patent GrantedMEAIIP / Competition
Japanese Patent Application Published for MEAI for Depression
depressionsource ↗
May 26, 2026
▲IND ClearanceCMND-100IND
Johns Hopkins IRB approval to advance CMND-100 Phase I/II trial to Parts B and C
Alcohol Use Disordersource ↗
Drug Pipeline Intelligence
D21
Pipeline Score $0M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.1x
rNPV / MCap Top 19%
Micro Cap (rank 740 of 912)
Percentile RankClearmind Medicine Inc. faces pipeline headwinds (21/100), with $14M risk-adjusted pipeline value, led by CMND-100 in Alcohol Use Disorder (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CMND-100 Small molecule | Alcohol Use Disorder | Phase 1 | NCT05913752 | 7% | $14M | RECRUITING | 84 | STALLED | B (62) | Dec 31, 2026 | LOW_RISK | MEDIUM May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
CMND-100 | Alcohol Use Disorder | Phase 1/2a | 2026-05-12 | 20 participants treated, 160 mg dose, no serious adverse events reported Read More | Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder Read More | |
CMND-100 | Alcohol Use Disorder | Phase 1/2a | 2026-05-12 | 20 participants treated, 160 mg dose, no serious adverse events reported Read More | Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder Read More | |
CMND-100 | Alcohol Use Disorder | Phase 1/2a | 2026-05-12 | 20 participants treated, 160 mg dose, no serious adverse events reported Read More | Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CMND
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CMND Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CMND▼ -1.9%today
Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative
Clearmind Medicine Inc. has submitted a response to the U.S. Department of Health and Human Services regarding its innovative treatment for Alcohol Use Disorder (AUD) using its non-hallucinogenic neuroplastogen, CMND-100. The submission aligns with the Great American Recovery Initiative, emphasizing the need for effective addiction treatments. Clearmind's approach aims to provide scalable and accessible solutions for those affected by AUD.
Read more →CMND▼ -9.4%on this newsshared move
Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI
Clearmind Medicine Inc. has reported progress in its formulation feasibility study for MEAI, focusing on intranasal delivery as a potential treatment for alcohol use disorder (AUD). The study demonstrated that MEAI can be effectively incorporated into a stable formulation, supporting further development. This approach aims to improve patient experience and address the limited treatment options available for AUD.
Read more →CMNDClearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength
Clearmind Medicine Inc. has been granted a new U.S. Patent No. 12,357,590 for its Binge Behavior Regulators, enhancing its intellectual property related to the MEAI molecule. This patent builds on a previously issued patent and is part of the company's strategy to develop non-hallucinogenic therapeutics for compulsive behaviors. Clearmind continues to expand its patent portfolio, aiming to address under-treated health problems.
Read more →CMNDClearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
Clearmind Medicine Inc. has successfully completed Part A of its Phase I/II trial for CMND-100, aimed at treating Alcohol Use Disorder. All 24 participants across four cohorts finished treatment as per the study protocol. The company is now reviewing the data and plans to advance to the next stage if results are favorable.
Read more →CMNDClearmind Medicine Granted U.S. Patent for Binge Behavior Regulators
Clearmind Medicine Inc. has been granted a U.S. Patent for its molecule MEAI, aimed at regulating binge behaviors such as excessive drinking and eating. This patent enhances the company's intellectual property portfolio and supports its clinical programs targeting alcohol use disorder. CEO Dr. Adi Zuloff-Shani emphasized the importance of this milestone in expanding therapeutic options for patients.
Read more →CMND▼ -6.8%on this newsshared move
Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial
Clearmind Medicine has successfully completed dosing for all 24 participants in Part A of its Phase I/II clinical trial for CMND-100, aimed at treating Alcohol Use Disorder. The trial, conducted under FDA oversight, showed a strong safety profile in interim results. The company expressed satisfaction with the rapid enrollment and execution across clinical sites.
Read more →CMNDCLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For The Three And Six Months Ended
ClearMind Medicine Inc. has released its condensed interim consolidated financial statements for the three and six months ended April 30, 2026. The company reported a net loss of $5,902,236 and an accumulated deficit of $33,781,960, reflecting ongoing financial challenges. Despite a significant increase in cash and cash equivalents to $11,415,719, the company experienced negative cash flows from operations. The ability to continue operations depends on securing future financing, as the company has not yet generated any revenue.
Read more →CMNDAGREEMENT This Agreement (this "Agreement") is entered into as of
Clearmind Medicine Inc. has entered into an agreement with accredited investors to amend its Securities Purchase Agreement. This amendment allows the company to issue $1,000,000 in Additional Notes, exceeding the standard Quarterly Limit. The terms of the agreement include a cash payment that equates to 90% of the principal amount and adjustments to the conversion price formula. The agreement is signed by key executives from both Clearmind and the investing parties.
Read more →CMND▲ +36.8%on this news
Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar
Clearmind Medicine Inc. will host a webinar on June 10, 2026, to discuss findings from its ongoing FDA-approved Phase I/IIa clinical trial of CMND-100, an oral drug for Alcohol Use Disorder. The event will feature insights from leading researchers at Yale and Johns Hopkins, and will include a live Q&A session. Clearmind aims to develop non-hallucinogenic therapeutics to address under-treated health issues, emphasizing the significance of their research and development efforts. Interested participants are encouraged to secure their spot for this informative session open to the public.
Read more →CMND▲ +46.1%on this news
Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment
Clearmind Medicine Inc. has filed a Japanese Patent Application for its non-hallucinogenic treatment MEAI, aimed at addressing depression. This move enhances the company's intellectual property portfolio, which already includes numerous patents globally. The market for depression treatments is expected to grow significantly, reflecting rising mental health awareness. Clearmind is also expanding its research into other mental health disorders and addictions.
Read more →CMND▲ +14.6%on this news· ran to +58% by day 3shared move
Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts
Clearmind Medicine has received approval from the Johns Hopkins Medicine Institutional Review Board to advance its Phase I/II clinical trial of CMND-100. This approval allows the company to proceed with Parts B and C of the study, which focuses on the tolerability, safety, and pharmacokinetics of CMND-100 in healthy volunteers and patients with Alcohol Use Disorder. The CEO expressed gratitude and optimism regarding the trial's potential impact.
Read more →CMND▼ -37.8%on this news
Clearmind Medicine Announces 1-for-10 Reverse Share Split
Clearmind Medicine Inc. has announced a 1-for-10 reverse share split effective May 21, 2026, to comply with Nasdaq's Minimum Bid Price Rule. The board approved this action to adjust the number of outstanding shares from approximately 10.2 million to about 1 million. The company remains focused on developing non-hallucinogenic therapeutics for various health issues.
Read more →CMND▼ -37.8%on this news
CONVERSION AGREEMENT This Conversion Agreement (this "Agreement") is entered into as of
Clearmind Medicine Inc. has entered into a Conversion Agreement with accredited investors, effectively converting $600,000 of its outstanding Convertible Notes into common shares. The agreement sets the conversion price at $0.30 per share, deviating from previous terms in the Notes. The Company also confirms that no Event of Default is present, signifying ongoing financial health. This agreement aims to facilitate clearer terms for investors and enhance capital structure.
Read more →CMND▼ -26.9%on this news· ran to -55% by day 1shared move
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications
Clearmind Medicine has signed a research agreement with Yissum Research to study MEAI's efficacy in combination with tirzepatide for obesity treatment. The preclinical study will explore MEAI's potential to enhance metabolic benefits and reduce weight regain after tirzepatide therapy. This collaboration builds on previous positive results from their earlier studies.
Read more →CMNDClearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.
Clearmind Medicine Inc.'s CEO, Dr. Adi Zuloff-Shani, has been appointed as a delegate to the Federal Policy Summit on Psychedelic Medicine, recently held in Washington, D.C. This summit aimed to unite federal officials and leading biopharma executives to discuss the advancement of psychedelic-derived therapies. Clearmind is actively conducting Phase IIa clinical trials for its non-hallucinogenic psychedelic compounds at prestigious institutions. Dr. Zuloff-Shani emphasized the importance of collaborative dialogue among stakeholders to foster responsible development in this emerging field.
Read more →CMNDClearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder
Clearmind Medicine has reached a significant milestone in its Phase I/IIa trial of CMND-100 for Alcohol Use Disorder, with 20 participants now treated. The latest cohort received a higher dose of the drug, following positive safety data from earlier groups. The trial is being conducted at several prestigious medical institutions, and the company expresses confidence in the drug's potential as a new treatment option.
Read more →CMND▼ -5.6%on this newsshared move
Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial
Clearmind Medicine Inc. will host a live webinar titled 'Inside MEAI' on June 10, 2026, to discuss new insights from the CMND-100 psychedelic clinical trial for Alcohol Use Disorder. The session will feature presentations from prominent clinical investigators and will include a Q&A segment. The company emphasizes the positive safety data and potential of its non-hallucinogenic treatment.
Read more →CMND▼ -9.6%on this news
Clearmind Medicine Announces Filing of Eu ropean Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD Vancouver, Canada
Clearmind Medicine Inc. has announced the filing of a European patent application for new psychedelic compounds that target the treatment of Post-Traumatic Stress Disorder (PTSD) and other mental health disorders. This development is part of an exclusive licensing agreement with Yissum Research Development Company, granting Clearmind global rights to these compounds. The market for PTSD treatments is expected to grow significantly, highlighting the potential for Clearmind’s innovations. Additionally, recent federal initiatives aim to accelerate research into psychedelic therapies, which may enhance Clearmind's position in the market.
Read more →CMND▼ -9.6%on this news
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD
Clearmind Medicine Inc. has filed a European patent application for novel psychedelic compounds aimed at treating PTSD and other mental health disorders. This move enhances the company's intellectual property position and aligns with a recent executive order promoting research into psychedelic therapies. The global PTSD treatment market is expected to grow significantly, indicating a promising opportunity for Clearmind's innovations.
Read more →CMND▼ -10.1%on this news
Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
Clearmind Medicine is evaluating its lead candidate, CMND-100 (MEAI), for FDA's Breakthrough Therapy Designation based on positive results from its Phase I/IIa clinical trial for Alcohol Use Disorder. The company believes that recent regulatory changes may support its eligibility for this designation, which is significant for treating serious conditions. However, no formal request has been submitted to the FDA yet.
Read more →CMND▲ +58.4%on this news
Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial
Clearmind Medicine Inc. announced that its proprietary drug CMND-100 has successfully met the primary endpoint in a Phase I/IIa clinical trial for Alcohol Use Disorder (AUD). The results from the trial's third cohort demonstrated a high safety profile with no serious adverse events reported. This positive outcome supports the advancement of CMND-100 as a potential treatment option for AUD.
Read more →CMND▲ +58.4%on this newsshared move
Clearmind Medicine Welcomes President Trump’s Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care
Clearmind Medicine has praised President Trump's Executive Order aimed at accelerating the review of psychedelic drugs for mental health treatment. This order is expected to enhance access to innovative therapies for veterans and others suffering from treatment-resistant conditions. Clearmind's compound, MEAI, is highlighted in recent legislation, furthering its mission to develop effective treatments.
Read more →CMND▲ +58.4%on this newsshared move
Clearmind Medicine Welcomes President Trump's Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care Vancouver, Canada, April 20 , 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc
Clearmind Medicine Inc. has expressed strong support for President Trump's recent Executive Order aimed at accelerating medical treatments for serious mental illnesses. The order prompts the FDA to prioritize review of certain psychedelic drugs as breakthrough therapies, enhancing access for patients. Clearmind's CEO highlighted the growing acceptance of psychedelic medicines as viable solutions for conditions like PTSD and depression. Furthermore, the company is progressing with clinical trials involving their lead candidate, CMND-100, approved for testing at prestigious institutions.
Read more →CMND▼ -28.6%on this newsshared move
Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial
Clearmind Medicine Inc. announced a positive recommendation from its Data and Safety Monitoring Board for the ongoing Phase I/IIa clinical trial of CMND-100, aimed at treating Alcohol Use Disorder. The recommendation follows the successful completion of the third cohort, with safety data indicating the drug was well tolerated. The trial will now advance to the fourth cohort with an increased dosage of 160mg.
Read more →CMND▼ -36.4%on this news· ran to -55% by day 1shared move
Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
Clearmind Medicine announced that its drug candidate CMND-100 has successfully met the primary endpoint in an FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder. The trial demonstrated a high safety profile with no serious adverse events reported. This promising outcome supports the drug's potential as a novel treatment option for patients suffering from moderate to severe AUD.
Read more →CMND▲ +22.7%on this news· ran to +33% by day 3
Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
Clearmind Medicine has successfully completed treatment and follow-up for 18 participants in its Phase I/IIa clinical trial of CMND-100 for Alcohol Use Disorder. The trial, which is FDA-approved, has shown strong momentum with the addition of four more participants at the Tel Aviv site. The study aims to evaluate the safety, tolerability, and preliminary efficacy of the drug candidate.
Read more →CMND▲ +10.4%on this news· ran to +47% by day 3shared move
Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
Clearmind Medicine Inc. has filed a patent application in India for next-generation psychedelic compounds aimed at treating mental health disorders and addiction. This move is part of the company's strategy to expand its global intellectual property portfolio. The new compounds are designed to provide safer and more effective treatment options compared to traditional psychedelics.
Read more →CMNDClearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder
Clearmind Medicine Inc. announced successful ongoing treatment of participants in its FDA-approved Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic oral drug candidate for Alcohol Use Disorder. The trial is taking place at prestigious U.S. institutions, including Yale University and Johns Hopkins University, where patients have shown continued safety and tolerability. This progress underscores the company's optimism regarding CMND-100's potential to serve as a breakthrough therapy. The company builds on positive recruitment momentum from prior cohorts as it advances its clinical efforts.
Read more →CMNDClearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies
Clearmind Medicine Inc. has announced the publication of six new patents in Hong Kong, focusing on innovative psychedelic-based combination therapies. These patents protect formulations that combine Palmitoylethanolamide (PEA) with various psychedelic compounds, aiming to enhance therapeutic potential and safety for mental health indications. The company continues to expand its intellectual property portfolio to address significant health challenges.
Read more →CMND▼ -5.9%on this news· ran to -18% by day 3shared move
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
Clearmind Medicine Inc. has filed a patent application in Hong Kong for a novel therapy combining MEAI and Palmitoylethanolamide to treat major depressive disorder. This innovative approach aims to provide a non-hallucinogenic alternative to traditional antidepressants, addressing a significant global market. The therapy's potential effectiveness could make it a safer and more accessible option for patients.
Read more →CMND▼ -11.6%on this newsshared move
CLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For The Three Months Ended
ClearMind Medicine Inc. reported its financial results for the three months ending January 31, 2026, revealing a significant net loss of $3.85 million compared to a net loss of $1.07 million during the same period last year. The company experienced an increase in cash reserves, expanding its cash and equivalents to $9.26 million. Despite this, an accumulated deficit of $31.73 million raises concerns about its financial sustainability. Overall, the report indicates ongoing challenges in generating revenue and managing operational costs.
Read more →CMND▼ -6.3%on this news· ran to -26% by day 3shared move
Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results
Clearmind Medicine Inc. has announced the continuation of participant enrollment for the third cohort of its Phase I/IIa clinical trial for CMND-100, a treatment for Alcohol Use Disorder (AUD). This follows positive topline results from prior cohorts, demonstrating safety and tolerability. The trial is taking place at renowned sites, including Yale University and Johns Hopkins University. Clearmind aims to develop CMND-100 as a safe, non-hallucinogenic option to address significant health issues related to alcohol use.
Read more →CMNDClearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
Clearmind Medicine Inc. has announced the publication of an international patent for a novel therapy that combines MEAI and Palmitoylethanolamide to target obesity and metabolic dysfunction-associated steatotic liver disease. This treatment aims to provide a safe, non-hallucinogenic alternative to current obesity medications. The company is positioned to capture a portion of the expanding global weight loss drugs market, which is projected to exceed $200 billion by 2035. CEO Dr. Adi Zuloff-Shani emphasized the company's commitment to developing innovative therapies for significant health challenges.
Read more →CMNDClearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
Clearmind Medicine has received approval from its Data and Safety Monitoring Board to advance to the next stage of its Phase I/IIa clinical trial for CMND-100, a treatment for Alcohol Use Disorder. The decision was based on positive safety results from the second cohort, which showed no serious adverse events. The trial aims to evaluate the safety and efficacy of CMND-100, with the next cohort set to administer a higher dose.
Read more →CMND▼ -8.1%on this news· ran to -19% by day 3
Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial
Clearmind Medicine announced additional positive safety results from the second cohort of its FDA-approved Phase I/IIa clinical trial for CMND-100, aimed at treating Alcohol Use Disorder. The results indicate no serious adverse events and continued good tolerability, reinforcing the favorable profile established in the first cohort. The trial is being conducted at leading medical centers, including Johns Hopkins University.
Read more →CMND▼ -6.9%on this news· ran to -20% by day 3shared move
Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI
Clearmind Medicine has entered a development agreement with Polyrizon to create an optimized intranasal formulation of its lead compound, MEAI. This collaboration aims to enhance the bioavailability and clinical advancement of MEAI, which targets addiction-related and other CNS disorders. The partnership combines Clearmind's neuroplastogen expertise with Polyrizon's intranasal delivery technology.
Read more →CMND▼ -5.8%on this news· ran to -39% by day 3shared move
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments
Clearmind Medicine Inc. announced the inclusion of its proprietary compound MEAI in the U.S. Congress's bipartisan legislation aimed at expanding veterans' access to innovative treatments. The Expanding Veterans' Access to Emerging Treatments Act of 2026 would enable the Department of Veterans Affairs to establish programs for investigational research on therapies like MEAI. This recognition marks a significant milestone for Clearmind and its efforts to address under-treated health issues among veterans.
Read more →CMND▲ +5.6%on this news
Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025
Clearmind Medicine Inc. has filed its Annual Report on Form 20-F for the fiscal year ending October 31, 2025, with the U.S. Securities and Exchange Commission. This report is accessible on both the SEC and Clearmind's investor relations website. The company focuses on developing psychedelic-derived therapeutics for health issues like alcohol use disorder and boasts a portfolio of 31 granted patents. Forward-looking statements in the report come with inherent risks and uncertainties.
Read more →CMNDClearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100
Clearmind Medicine has announced the successful completion of treatment for all patients in the second cohort of its Phase I/IIa clinical trial for CMND-100, aimed at treating Alcohol Use Disorder. This follows positive results from the first cohort, which indicated a favorable safety profile and preliminary efficacy. The trial is ongoing, with topline results expected in the coming months.
Read more →CMND▲ +9.9%on this news· ran to +41% by day 3
Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement
Clearmind Medicine Inc. has announced that it has regained compliance with Nasdaq's minimum bid price requirement after its shares closed above $1.00 for ten consecutive business days. This follows a notification from Nasdaq regarding non-compliance due to a prior closing price below the required threshold. The company continues to focus on developing innovative psychedelic-derived therapeutics.
Read more →CMND▼ -5.8%on this news· ran to -23% by day 3
Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for Future Growth
Clearmind Medicine Inc. has reported significant advancements in 2025, particularly with its lead candidate CMND-100 for the treatment of Alcohol Use Disorder. The company made notable progress in its FDA-approved Phase I/IIa clinical trial, achieving successful dosing and positive safety results. Additionally, Clearmind expanded its global presence through multiple international patent filings. Looking ahead, the company aims to continue advancing its clinical pipeline and enhancing shareholder value.
Read more →CMNDClearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100
Clearmind Medicine Inc. has announced the successful completion of patient enrollment for the second cohort in its FDA-approved Phase I/IIa trial evaluating CMND-100, aimed at treating Alcohol Use Disorder. This follows promising early results from the first cohort, which indicated a favorable safety profile and preliminary efficacy. The rapid recruitment of patients across leading clinical sites highlights the effectiveness of their collaboration. Dosing for the second cohort is expected to start soon, with topline results anticipated in the upcoming months.
Read more →CMNDClearmind Medicine's MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment
Clearmind Medicine announced the publication of a review article validating the potential therapeutic effects of its candidate MEAI in the treatment of alcohol use disorder (AUD). The review, led by experts from Yale School of Medicine, highlights MEAI’s favorable pharmacological profile and compares it to classical psychedelics like LSD and MDMA. MEAI is posited to provide treatment benefits with lesser subjective experiences and reduced adverse effects. This publication is anticipated to enhance interest and support from the medical community regarding MEAI's development.
Read more →CMNDClearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
Clearmind Medicine Inc. has successfully regained compliance with Nasdaq's Minimum Stockholders' Equity Requirement as of December 10, 2025. This was confirmed through a notification letter from Nasdaq based on the Company's filing on December 5, 2025. While the news is positive, Nasdaq will continue to monitor the Company's compliance. Any future failure in maintaining the required equity could lead to the risk of delisting from the exchange, highlighting the need for vigilance in financial management.
Read more →CMND▼ -6.1%on this news· ran to -44% by day 3shared move
Clearmind Medicine Announces 1-for-40 Reverse Share Split
Clearmind Medicine Inc. has announced a 1-for-40 reverse share split of its common stock, effective December 15, 2025. This move aims to help the company comply with Nasdaq's Minimum Bid Price Rule, following board approval on November 12, 2025. Post-split, the total number of outstanding common shares will decrease significantly from approximately 60 million to about 1.5 million, while the company's authorized share capital remains consistent. The need for a reverse split raises questions about the company's financial health and market confidence.
Read more →CMNDClearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
Clearmind Medicine Inc. received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, as its closing share price fell below $1.00 for 30 consecutive days. The company has been granted a 180-day compliance period, until June 2, 2026, to meet the least closing bid price of $1.00 for at least 10 consecutive days. During this period, shares will continue to be traded on Nasdaq. If compliance is not achieved, Clearmind may apply for a second compliance period, but faces potential delisting risks.
Read more →CMND▼ -9.9%on this news· ran to -23% by day 1shared move
Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder
Clearmind Medicine has announced a significant milestone in its Phase I/IIa clinical trial for Alcohol Use Disorder (AUD) with the first participant dosed with CMND-100 at Hadassah-University Medical Center in Jerusalem. This trial aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of the drug candidate. Early results from the first cohort have been positive, leading to the Data and Safety Monitoring Board recommending the trial continue. The company’s goal is to provide innovative treatments for individuals affected by AUD.
Read more →CMND▼ -6.9%on this newsshared move
Clearmind Medicine Charges Forward in Alcoholism Treatment: Positive Cohort Data, Full DSMB Approval, and New Elite Site Joins the Clinical Trial
Clearmind Medicine Inc. has announced significant advancements in its Phase I/IIa clinical trial for CMND-100, aimed at treating Alcohol Use Disorder. Key milestones include positive results from the first cohort and unanimous approval from the Data and Safety Monitoring Board to proceed. Additionally, a new clinical site in Israel has been activated to enhance patient recruitment efforts. The current therapeutic approach utilizes novel neuroplastogen-derived compounds to improve treatment efficacy for millions affected by AUD.
Read more →CMNDCLEARMIND MEDICINE INC. MANAGEMENT INFORMATION CIRCULAR For the Annual General and Special Meeting of Shareholders to be held on
Clearmind Medicine Inc. has announced the details for its Annual General and Special Meeting of Shareholders, scheduled for December 29, 2025. The meeting will be conducted virtually through a live webcast on Zoom. Shareholders are encouraged to vote via proxy if unable to attend in person. Key topics of discussion will include the election of directors, the appointment of an auditor, and other business matters.
Read more →CMND▼ -19.4%on this newsshared move
Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial
Clearmind Medicine Inc. has commenced patient enrollment at the Tel Aviv Sourasky Medical Center for its Phase I/IIa clinical trial of CMND-100, targeting Alcohol Use Disorder. The prestigious center has recruited its first participant, enhancing the study's global recruitment momentum. The trial evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100, with encouraging early results showing no serious adverse events. This development marks a significant milestone for Clearmind as they progress toward potentially revolutionizing treatment options for AUD.
Read more →CMND▲ +8.4%on this newsshared move
Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/IIa Clinical Trial for CMND-100 Following Positive Interim Safety Review
Clearmind Medicine announced the continuation of its Phase I/IIa clinical trial for CMND-100 following a positive interim safety review by the independent Data and Safety Monitoring Board (DSMB). The DSMB found no serious adverse events and confirmed a good safety profile for the proprietary, non-hallucinogenic neuroplastogen intended for treating Alcohol Use Disorder. Clearmind's CEO expressed confidence in the therapy's potential and highlighted the strong adherence to the study protocol among participants. The firm aims to accelerate enrollment in the trial to advance this promising treatment.
Read more →CMNDClearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site
Clearmind Medicine has initiated its FDA-approved Phase I/IIa clinical trial for CMND-100 at Hadassah Medical Center, expanding its study on a non-hallucinogenic treatment for Alcohol Use Disorder. The trial aims to evaluate the safety and efficacy of the drug, with promising early data showing a favorable safety profile and strong patient adherence. This milestone highlights the growing momentum behind CMND-100 as a potential solution for millions suffering from AUD.
Read more →CMND▼ -21.8%on this news· ran to -34% by day 3shared move
Clearmind Medicine Announces Positive Top-Line Results from First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
Clearmind Medicine Inc. announced positive top-line results from the first cohort of its FDA-approved Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic drug candidate aimed at treating Alcohol Use Disorder. The results indicated a favorable safety profile and high adherence to the treatment regimen among participants. Conducted at esteemed institutions like Johns Hopkins and Yale, the trial supports continued evaluation of CMND-100 as a promising therapeutic option in a field with limited existing treatments for AUD.
Read more →CMNDClearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
Clearmind Medicine Inc. has filed an Israeli patent for a novel non-hallucinogenic treatment targeting depression, combining 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines like Palmitoylethanolamide (PEA). This patent reflects a collaboration with Neurothera Labs and aims to address a significant worldwide health issue, as depression affects over 280 million people. The company's CEO highlighted the potential of this innovation to create new treatment avenues for mental health conditions, further strengthening Clearmind's intellectual property portfolio.
Read more →CMND▲ +11.6%on this newsshared move
Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center
Clearmind Medicine Inc. has received final approval from Hadassah Medical Center in Jerusalem to expand its Phase 1/2a clinical trial for its CMND-100 drug candidate aimed at treating Alcohol Use Disorder (AUD). The trial involves collaborations with leading medical institutions and seeks to evaluate the safety and efficacy of the treatment in addressing alcohol cravings. This approval highlights the company's commitment to tackling AUD, which poses a significant public health challenge worldwide.
Read more →CMND▼ -32.3%on this newsshared move
Clearmind Medicine Announces Notice of Patent Publication for Depression Treatment
Clearmind Medicine Inc. has announced the publication of a patent for its non-hallucinogenic compound MEAI, aimed at treating depression. This compound has shown promise in preclinical studies for enhancing mood regulation and reducing anhedonia. The patent strengthens Clearmind's intellectual property portfolio, which includes protections for various mental health and addiction disorders.
Read more →CMNDClearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
Clearmind Medicine has completed the first cohort treatment in its Phase I/IIa clinical trial for CMND-100, aimed at treating Alcohol Use Disorder. Six patients have been enrolled across leading research centers, including Johns Hopkins and Yale. The trial will assess safety, tolerability, and preliminary efficacy of the therapy, addressing a substantial market need.
Read more →CMNDClearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
Clearmind Medicine Inc. received a Notification Letter from Nasdaq regarding its non-compliance with the minimum stockholders' equity requirement. The company reported a stockholders' equity of $1,065,668, below the required $2,500,000. Despite this, the company’s operations are unaffected, and it has 45 days to submit a compliance plan. Shares continue to trade on Nasdaq.
Read more →CMNDClearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing
Clearmind Medicine Inc. has filed a patent application in South Korea for its compound MEAI, aimed at treating depression. This filing enhances the company's global intellectual property portfolio, which now includes protections in multiple jurisdictions. MEAI is a non-hallucinogenic neuroplastogen that may improve mood regulation and alleviate depressive symptoms. Clearmind continues to prepare for clinical development and commercialization of this innovative treatment.
Read more →CMNDClearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy
Clearmind Medicine has published a U.S. patent application for its non-hallucinogenic compound MEAI, aimed at treating cocaine addiction. This development enhances the company's intellectual property portfolio and highlights the urgent need for effective treatments in this area. The global market for cocaine addiction treatment is expected to grow significantly, emphasizing the potential impact of MEAI.
Read more →CMNDClearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
Clearmind Medicine Inc. has completed the treatment of the last patient in the first cohort of its FDA-approved Phase I/IIa clinical trial for CMND-100, a novel oral drug candidate aimed at treating Alcohol Use Disorder (AUD). The trial, which involved six patients enrolled across prominent institutions such as Johns Hopkins University and Yale School of Medicine, seeks to assess the safety, tolerability, and potential efficacy of the drug. The successful enrollment and treatment of patients underscore the urgent need for effective AUD therapies amid a global market projected to exceed $20 billion by 2032. Clearmind is committed to advancing its psychedelic-derived solutions to address addiction effectively.
Read more →CMNDClearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar
Clearmind Medicine's CEO, Dr. Adi Zuloff-Shani, will speak at the 'Women in Psychedelic Leadership' webinar on October 29, 2025. The event, hosted by the Psychedelic Association of Canada, aims to discuss women's roles in psychedelic research and governance. Dr. Zuloff-Shani's extensive experience in therapeutics development will provide valuable insights into the future of psychedelic medicine.
Read more →CMNDClearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement
Clearmind Medicine has appointed Mary-Elizabeth Gifford as Chief of Global Impact to enhance its US partnerships and regulatory advocacy. Gifford, previously with Psyence BioMed, brings extensive experience in psychedelic policies and collaborations with government officials. Her role aims to position Clearmind as a leader in ethical psychedelic therapeutics while advancing clinical trials at prestigious institutions.
Read more →CMNDClearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
Clearmind Medicine has announced the enrollment of the last patient in the first cohort of its FDA-approved Phase I/IIa clinical trial for its drug candidate CMND-100, aimed at treating Alcohol Use Disorder (AUD). The trial includes six participants from prestigious institutions such as Johns Hopkins University and Yale School of Medicine. It is designed to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100 while exploring its efficacy in reducing alcohol cravings and consumption. Clearmind's progress reflects a commitment to developing innovative solutions for AUD, a condition affecting millions globally.
Read more →CMNDClearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders
Clearmind Medicine Inc. has announced the publication of a U.S. patent application for a combination therapy targeting binge behavior disorders. The therapy combines 5-methoxy-2-aminoindane (MEAI) with N-Acylethanolamines, such as Palmitoylethanolamide (PEA). This innovative approach aims to address issues like alcohol consumption, binge eating, and other compulsive behaviors by leveraging MEAI's neuroplastic properties. Clearmind’s ongoing collaboration with SciSparc Ltd. underpins this publication, contributing to an expanding patent portfolio focused on addiction treatments.
Read more →CMNDClearmind Medicine’s Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies
Clearmind Medicine convened its inaugural Annual Scientific Advisory Board meeting, bringing together experts in psychiatry and addiction research to discuss the development of its lead candidate MEAI, which is currently in clinical trials for Alcohol Use Disorder. The Board emphasized MEAI's unique safety profile and potential to serve as an effective treatment for various health issues, including metabolic disorders. The insights from these experts are expected to inform Clearmind's clinical development strategies and partnerships. Clearmind's robust intellectual property portfolio was also reviewed during the meeting.
Read more →CMNDClearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities
Clearmind Medicine Inc. has announced the execution of securities purchase agreements that allow it to issue convertible promissory notes totaling up to $10 million. Initial funds of $500,000 from the sale of notes will support working capital and potential strategic acquisitions. The company, dedicated to developing psychedelic-derived therapeutics, aims to address significant under-treated health problems, including alcohol use disorder. The success of this financing initiative is expected to bolster its growth and research capabilities.
Read more →CMNDCLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For The Three and Nine Months Ended
ClearMind Medicine Inc. disclosed its condensed interim consolidated financial statements for the three and nine months ended July 31, 2025. The company has not generated any revenues during this period and reported a net loss of $3,169,141, with an accumulated deficit reaching $27,191,882. ClearMind's current assets have declined significantly compared to the previous year, suggesting financial instability. The company's management acknowledges the need for future cash flow generation or additional financing to sustain operations.
Read more →CMNDClearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
Clearmind Medicine Inc. has announced the publication of an international patent application for a novel combination therapy targeting obesity and high blood sugar. This therapy combines Clearmind's proprietary compound MEAI with SciSparc's PEA to address metabolic syndrome. The announcement highlights the significance of their ongoing collaboration and the filing of multiple patent families. The company's CEO expressed optimism about redefining therapeutic approaches for metabolic conditions through this innovative therapy.
Read more →CMNDClearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center
Clearmind Medicine Inc. has obtained IRB approval from Hadassah Medical Center for its Phase 1/2a clinical trial of CMND-100, targeting Alcohol Use Disorder. This milestone follows the FDA's clearance of the Investigational New Drug application and previous approvals from other clinical sites. The trial aims to assess the drug's safety, tolerability, and preliminary efficacy in patients. Leading institutions like Yale and Johns Hopkins are collaborating in this groundbreaking research effort.
Read more →CMNDClearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
Clearmind Medicine Inc. has filed an international patent application for a combination therapy aimed at treating obesity and metabolic dysfunction-associated steatotic liver disease. This novel treatment includes MEAI and Palmitoylethanolamide (PEA), which may address significant global health issues where current treatment options are limited. The patent application reflects Clearmind's dedication to developing innovative, science-backed therapeutics to support those affected by these conditions. The company's collaboration with SciSparc Ltd. underlines its commitment to advancing therapeutic solutions in the biotech sector.
Read more →CMNDwww.ClearmindMedicine.com Novel Psychedelics for Treating Addictions, Obesity & Mental Health Corporate and Science Presentation | July 2025 NASDAQ: CMND FSE: CWY0 Clearmind Medicine Inc. Clearmind Medicine Inc. Page 2 A
Clearmind Medicine Inc. presented its strategies and advancements in developing psychedelic treatments aimed at addressing addiction, obesity, and mental health issues. The company emphasizes its flagship molecule, MEAI, which shows potential for treating alcohol use disorder. Clearmind has initiated Phase I/Iia clinical trials in four locations globally, highlighting ongoing efforts to validate their product's efficacy. However, the presentation includes caution regarding the inherent uncertainties and risks associated with forward-looking statements concerning future performance and market potential.
Read more →CMNDClearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease Vancouver, Canada
Clearmind Medicine Inc. has announced the filing of an international patent application for a groundbreaking combination therapy utilizing MEAI and PEA, aimed at combatting obesity and fatty liver disease. This innovation is particularly relevant given the rising prevalence of these health issues globally. The company emphasizes its commitment to addressing significant medical needs by developing science-backed therapies. However, they acknowledge uncertainties regarding the patent approval process and the efficacy of their innovative treatment.
Read more →CMNDClearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder
Clearmind Medicine Inc. has announced the successful initiation of the Tel Aviv Sourasky Medical Center as a clinical site for its Phase I/IIa trial of CMND-100, a drug candidate for Alcohol Use Disorder (AUD). This milestone is part of a multinational study that includes notable institutions like Yale and Johns Hopkins, aiming to assess the drug's safety and efficacy. The trial seeks to address significant health issues, as AUD impacts millions worldwide. Clearmind's use of a novel psychedelic-derived therapeutic, CMND-100, shows potential based on promising preclinical results.
Read more →CMNDClearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled
Clearmind Medicine Inc. has expanded its Phase I/IIa clinical trial for CMND-100, its treatment candidate for Alcohol Use Disorder (AUD), by activating a new site at Johns Hopkins University School of Medicine and enrolling its first participant there. This expansion follows earlier successes, including the enrollment of a participant at Yale School of Medicine. The trial aims to evaluate CMND-100's safety, tolerability, and potential effectiveness in reducing alcohol cravings and consumption. Clearmind's efforts signify its commitment to providing innovative solutions for AUD.
Read more →CMNDClearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center
Clearmind Medicine Inc. has announced IRB approval for its Phase 1/2a clinical trial of CMND-100 at Tel Aviv Sourasky Medical Center for treating Alcohol Use Disorder. This milestone allows patient enrollment at a prestigious clinical site in Israel, alongside contributions from major institutions like Yale and Johns Hopkins. The trial aims to assess the safety and efficacy of the MEAI-based oral drug candidate for individuals affected by AUD, addressing a significant global health issue. Clearmind is optimistic about advancing its mission to develop innovative psychedelic-derived therapies.
Read more →CMNDClearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder
Clearmind Medicine Inc. has achieved a notable milestone by dosing the first participant in its Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder with its drug candidate CMND-100. This event, which took place at prominent clinical sites including Yale and Johns Hopkins, represents the first instance of their innovative treatment being administered in a clinical setting. The trial will assess the safety, tolerability, and initial efficacy of CMND-100 in reducing alcohol cravings among participants. This significant step brings the company closer to potentially developing a new therapeutic solution for millions affected by AUD globally.
Read more →CMNDClearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market
Clearmind Medicine Inc. has expanded its Phase I/IIa clinical trial for CMND-100 by adding Hadassah-University Medical Center in Jerusalem, Israel, as a new site. This trial aims to evaluate the safety and efficacy of CMND-100, a drug candidate for treating Alcohol Use Disorder. The inclusion of leading medical institutions is expected to enhance patient recruitment and accelerate data collection. Alcohol Use Disorder represents a significant global health challenge, with many individuals seeking effective treatment options.
Read more →CMNDClearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment
Clearmind Medicine Inc. has enrolled the first patient in its Phase I/IIa clinical trial for CMND-100, a proprietary MEAI-based oral drug targeting Alcohol Use Disorder. The trial, conducted at Yale School of Medicine and other locations, will assess the safety and efficacy of the treatment. The enrollment symbolizes a pivotal step in the development of a potentially groundbreaking therapeutic solution for a significant global health issue.
Read more →CMNDClearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics
Clearmind Medicine Inc. has engaged a prominent political consulting firm to advance its mission of integrating psychedelic therapeutics into mainstream healthcare. This collaboration aims to navigate regulatory challenges and educate policymakers about the therapeutic potential of psychedelics. Clearmind's lead candidate, CMND-100, is currently undergoing Phase I/IIa clinical trials, supported by research at prestigious institutions. The partnership reflects Clearmind's commitment to facilitating access to innovative mental health treatments using psychedelics.
Read more →CMNDClearmind Medicine Adds Leading Israeli Clinical Site to Its Ongoing Clinical Trial for Alcohol Use Disorder
Clearmind Medicine Inc. has expanded its Phase I/IIa clinical trial for CMND-100 to include Tel Aviv Sourasky Medical Center in Israel. This addition follows the enrollment of the first patient earlier in June 2025 and aims to evaluate the drug's efficacy for Alcohol Use Disorder. The trial will be led by Dr. David Zeltser and includes other esteemed institutions such as Yale and Johns Hopkins. This move enhances Clearmind's clinical capabilities and underscores its commitment to addressing AUD, a significant global health issue.
Read more →CMNDCLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For The Three and Six Months Ended
Clearmind Medicine Inc. released its condensed interim consolidated financial statements for the periods ending April 30, 2025. The company reported a net loss of $1,855,549 and an accumulated deficit of $25,878,290 with no revenues generated. While there has been an increase in share capital, significant financial losses and a negative cash flow from operations raise doubts about the company's ability to continue as a going concern. Management suggests that obtaining additional financing will be crucial for the company's future operations.
Read more →CMNDClearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics
Clearmind Medicine Inc. has partnered with a prominent government and political affairs consulting firm to promote and advance psychedelic-based treatments. This collaboration aims to facilitate the integration of psychedelic therapies into mainstream healthcare by advocating for science-based regulatory frameworks. Clearmind recognizes the importance of navigating regulatory challenges, particularly for their lead candidate CMND-100, which is undergoing clinical trials for alcohol use disorder at renowned research institutions. The company emphasizes its commitment to enhancing access to potentially transformative mental health treatments.
Read more →CMNDClearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment
Clearmind Medicine Inc. has announced the enrollment of the first patient in its Phase I/IIa clinical trial for CMND-100, an oral drug targetting Alcohol Use Disorder (AUD). This significant development, occurring at Yale School of Medicine, evaluates CMND-100's safety and efficacy in reducing alcohol cravings. The company aims to address the substantial unmet medical needs in AUD, which affects hundreds of millions globally. Clearmind is optimistic about the transformative potential of its innovative treatment approach within the growing substance use disorder market.
Read more →CMNDClearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts
Clearmind Medicine Inc. is set to host a live webinar titled "Gazing Through the Crystal Ball" on May 21, 2025. The event will gather leading experts in psychedelic science to discuss the shifting landscape influenced by FDA policies and industry developments. Notable speakers include Rick Doblin and Robin Carhart-Harris, who will share insights into psychedelic therapies and their potential regulatory futures. This webinar aims to highlight opportunities in the rapidly evolving psychedelic market.
Read more →CMNDClearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
Clearmind Medicine Inc. announced the publication of a European patent covering its proprietary psychedelic-based combination therapy for cocaine addiction. This therapy includes MEAI and N-Acylethanolamines, and is supported by positive results from preclinical trials conducted at Bar-Ilan University. The patent is a significant step in Clearmind's strategy to protect its intellectual property for addiction treatments and is part of a collaboration with SciSparc Ltd. to explore the therapeutic potential of these compounds.
Read more →CMNDClearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
Clearmind Medicine Inc. has announced the filing of an international patent application for a new treatment directed at eating disorders, specifically anorexia and bulimia. This application covers the use of 3-Methylmethcathinone (3-MMC) combined with Palmitoylethanolamide (PEA), aiming to tackle the neurobiological and psychological complexities of these conditions. The company's CEO emphasized their commitment to creating innovative solutions for underserved mental health issues and expanding their drug development pipeline, despite recognizing the challenges of obtaining patent approval.
Read more →CMNDClearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites
Clearmind Medicine Inc. has successfully initiated its Phase I/IIa clinical trial for Alcohol Use Disorder (AUD) at all planned clinical sites, including Yale School of Medicine and Johns Hopkins University. The company has completed all necessary preparations, including FDA approval and institutional review board clearances. The trial aims to explore its innovative treatment, CMND-100, which represents a potential advancement in addressing a significant public health issue affecting many individuals. Patient enrollment is set to begin shortly, marking a critical milestone for the company.
Read more →CMNDClearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior
Clearmind Medicine Inc. announced that it has received a Notice of Allowance for a patent regarding its MEAI treatment aimed at binge behavior. This new patent bolsters the company's intellectual property portfolio, providing additional protection for its innovative therapeutic approaches. CEO Dr. Adi Zuloff-Shani highlighted that this development underscores the potential for the MEAI program and is a crucial step in establishing their position in the psychedelic therapeutic market. Clearmind's efforts focus on developing treatments for underserved health issues, including alcohol use disorder.
Read more →CMNDClearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism
Clearmind Medicine Inc. has launched its first U.S. clinical site for the Phase I/IIa trial of its innovative treatment, CMND-100, aimed at addressing Alcohol Use Disorder. The trial will be conducted at Johns Hopkins University, with additional sites planned at Yale and in Israel. This marks a significant step towards understanding the safety and efficacy of CMND-100, which could provide a novel approach to treating addiction issues. The initiative is crucial given the global challenge posed by Alcohol Use Disorder.
Read more →CMNDClearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder
Clearmind Medicine Inc. has launched its Phase I/IIa clinical trial for CMND-100 at its first U.S. site, Johns Hopkins University. This trial aims to evaluate the safety, tolerability, and pharmacokinetics of CMND-100 in patients with Alcohol Use Disorder (AUD). Notably, the study will also assess the drug's early efficacy in reducing alcohol cravings and consumption. The trial marks a critical step in Clearmind's objective to provide innovative drug solutions for addiction and establishes collaboration with esteemed clinical institutions.
Read more →CMNDClearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
Clearmind Medicine Inc. has announced the publication of an international patent application in collaboration with Yissum Research Development Company. The patent covers innovative psychedelic-based compounds aimed at treating mental health disorders and addiction. CEO Dr. Adi Zuloff-Shani highlighted the promise of their collaboration in advancing safe and effective solutions for these under-treated conditions. This application is part of a comprehensive strategy to enhance Clearmind's intellectual property and product offerings in the mental health space.
Read more →CMNDClearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment
Clearmind Medicine Inc. has launched its Electronic Data Capture (EDC) system to support a Phase I/II clinical trial of its MEAI-based treatment for Alcohol Use Disorder. The EDC system will enable real-time data collection and monitoring across participating sites, ensuring compliance and protocol integrity throughout the trial. By using this technology, Clearmind aims to evaluate the safety, tolerability, and efficacy of its innovative psychedelic-derived compound in individuals suffering from alcohol addiction.
Read more →CMNDClearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
Clearmind Medicine Inc. has announced that its drug candidate CMND-100 has reached the U.S., facilitating the upcoming initiation of its FDA-approved Phase I/IIa clinical trial for treating Alcohol Use Disorder. This drug, based on MEAI, aims to reduce alcohol consumption and cravings. The clinical trials are set to take place at prestigious institutions like Yale and Johns Hopkins, marking a significant step in advancing potential treatment for the over 28 million adults in the U.S. affected by AUD.
Read more →CMNDClearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
Clearmind Medicine Inc. has signed a non-binding Letter of Intent with Polyrizon Ltd. to develop an intranasal formulation for its psychedelic-based treatments. This collaboration aims to enhance the bioavailability and therapeutic effect of Clearmind's proprietary drug candidate MEAI, alone or in combination with PEA. The partnership will explore the advantages of intranasal delivery methods, which may offer faster absorption and improved patient compliance. Both companies plan to conduct research to validate the effectiveness of intranasal administration for this treatment approach.
Read more →CMNDClearmind Medicine Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients
Clearmind Medicine Inc. has initiated its Phase I/IIa clinical trial for CMND-100, a novel treatment targeting Alcohol Use Disorder (AUD). This represents the first clinical use of the proprietary drug platform and aims to evaluate the safety, tolerability, and pharmacokinetics of CMND-100 in patients with AUD. The trial will take place at sites including IMCA in Israel, Yale School of Medicine, and Johns Hopkins University, targeting a major global health issue. Preliminary efficacy evaluations will assess the drug's impact on alcohol cravings and consumption.
Read more →CMNDClearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea
Clearmind Medicine Inc. announced the publication of a new patent for its innovative treatment of cocaine addiction, focusing on a combination of MEAI and N-Acylethanolamines. This patent follows promising preclinical trials indicating MEAI can reduce cocaine cravings without adversely affecting natural reward responses. The company is expanding its patent portfolio and collaborating with SciSparc to further explore this treatment. Clearmind's dedication to developing psychedelic therapies for addiction represents a significant advancement in addressing under-treated health problems.
Read more →CMNDClearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico
Clearmind Medicine Inc. has announced the publication of a patent in Mexico for its innovative combination therapy aimed at treating binge behaviors, including alcohol consumption and shopping. This development resulted from a collaboration with SciSparc Ltd., focusing on integrating psychedelic compounds with N-Acylethanolamines. Clearmind's intellectual property portfolio is robust, consisting of 31 patents, and they are committed to further expanding their patent holdings in the future.
Read more →CMNDClearmind Medicine Announces Shareholders Meeting Results
Clearmind Medicine Inc. announced that all resolutions put forth at its January 6, 2025, shareholders meeting were approved, indicating strong support from shareholders. Key decisions included the appointment of auditors and the establishment of an equity incentive plan. The company's commitment to expanding its intellectual property portfolio was also highlighted. Clearmind focuses on developing psychedelic-derived therapeutics for under-treated health issues.
Read more →CMNDClearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
Clearmind Medicine Inc. has announced the publication of a European patent application for its combination therapy of MEAI and N-Acylethanolamines aimed at treating binge behavior. The company is collaborating with SciSparc Ltd., focusing on integrating psychedelic compounds in their therapeutic approaches. Clearmind has previously filed 13 patents in various jurisdictions, positioning itself as a leader in developing solutions for under-treated behavioral health issues. Despite the positive outlook, challenges such as approval uncertainties and inherent risks in therapeutic development remain.
Read more →CMNDClearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office
Clearmind Medicine Inc. has received a patent from the Macau International Intellectual Property Office for its MEAI-based binge behavior treatment, aimed at addressing substance addictions. This patent is part of a broader strategy to strengthen the company's intellectual property portfolio, which now includes 31 patents across 18 families. The CEO highlighted the potential impact of their treatments on individuals struggling with addiction, further supporting the company's innovation in the psychedelic space.
Read more →CMNDClearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
Clearmind Medicine Inc. has entered into a non-binding agreement with Dr. Glitter Pty Ltd to collaborate on developing MEAI-based alcohol alternatives. This product aims to provide the enjoyable sensations of drinking alcohol without its negative health effects. The planned ActivCrystal™ format will allow users to sprinkle the alcohol substitute on food or drinks, targeting the urgent need to address alcohol misuse. CEO Dr. Adi Zuloff-Shani expressed optimism about the partnership’s potential to transform social drinking habits.
Read more →CMNDClearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial
Clearmind Medicine Inc. has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, aimed at treating alcohol use disorder (AUD). The trial will take place at Yale School of Medicine under the direction of Dr. Anahita Bassir Nia. This approval marks a key milestone in Clearmind's clinical program and supports the company's effort to evaluate CMND-100's safety and efficacy. The company aims to provide a novel solution for a widely under-treated condition, with excessive alcohol use linked to significant global mortality.
Read more →CMNDClearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format
Clearmind Medicine Inc. has entered a non-binding term sheet with Dr. Glitter Pty Ltd to co-develop a psychedelic-based alcohol substitute utilizing the innovative ActivCrystal technology. This collaboration aims to create a product that offers the sensations of alcohol without the associated health risks. Once a definitive agreement is in place, the companies will work towards bringing this product to market, targeting alcohol misuse, which is a widespread health issue. Both parties express enthusiasm for the potential impact of their partnership on modern social drinking practices.
Read more →CMNDCLEARMIND MEDICINE INC. MANAGEMENT INFORMATION CIRCULAR For the Annual and Special Meeting of Shareholders to be held on
Clearmind Medicine Inc. has announced its Annual and Special Meeting of Shareholders scheduled for January 6, 2025. The meeting will be held virtually via Zoom, allowing shareholders to participate remotely. The agenda includes key management proposals such as the approval of financial statements, appointment of directors, and an equity incentive plan. Shareholders are encouraged to vote by proxy or attend the meeting if they are unable to be present in person.
Read more →CMNDClearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site
Clearmind Medicine Inc. has announced that it has received Institutional Review Board (IRB) approval for its Phase I/IIa clinical trial of CMND-100, which aims to treat patients with alcohol use disorder. This trial will take place at multiple sites, including Johns Hopkins University and Yale School of Medicine, alongside an Israeli center. The trial focuses on assessing the safety, tolerability, and pharmacokinetics of the innovative treatment, with the hope of addressing a significant health challenge related to alcohol addiction.
Read more →CMNDClearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
Clearmind Medicine Inc. has announced the publication of an international patent application for its novel combination therapy utilizing Ibogaine and N-Acylethanolamines. This innovative therapy is aimed at addressing mental health and addiction issues, building on successful collaborations with SciSparc Ltd. While the therapy shows promise in treating substance use disorders, there are known risks associated with Ibogaine usage that could pose safety concerns. Clearmind is committed to advancing its position in the psychedelics space by developing a diverse patent portfolio.
Read more →CMNDClearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
Clearmind Medicine Inc. has submitted an international patent application for novel psychedelic compounds aimed at treating PTSD, collaborating with Yissum Research Development Company. These compounds intend to address significant gaps in current PTSD therapies, which are limited in efficacy and associated with side effects. The global PTSD treatment market is projected to grow significantly, underscoring the urgency for effective new treatments. Clearmind's CEO highlighted the importance of their innovative developments in responding to growing mental health treatment needs.
Read more →CMNDClearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
Clearmind Medicine Inc. has announced the publication of an international patent application for its innovative combination treatment utilizing MDMA and N-Acylethanolamines to enhance safety and efficacy in mental health and addiction therapies. The company is collaborating with SciSparc Ltd. to develop these combination therapies aimed at addressing significant safety concerns associated with MDMA. In doing so, Clearmind aims to reduce the required dosages of MDMA while maintaining its therapeutic effects, signalling a strategic commitment to advancing novel treatments in this field.
Read more →CMNDClearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
Clearmind Medicine Inc. has announced the publication of its patent application for a combination treatment utilizing ketamine and N-Acylethanolamines. This application is the result of a collaboration with SciSparc Ltd., focusing on developing novel therapies aimed at addressing central nervous system disorders. Both companies are exploring the efficacy of combining SciSparc's Palmitoylethanolamide with Clearmind's psychedelic compound, MEAI. The collaboration aims to enhance treatment effectiveness while reducing side effects for conditions such as addictions and mental health issues.
Read more →CMNDClearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment
Clearmind Medicine Inc. has been granted a new patent by the U.S. Patent and Trademark Office for its MEAI-based treatment targeting binge behavior. The patent includes methods for regulating alcohol consumption and controlling binge behavior using the psychedelic compound MEAI. This development adds to Clearmind's robust intellectual property portfolio, consisting of 29 granted patents across key markets. The company aims to address Alcohol Use Disorder and related conditions through innovative therapeutic approaches.
Read more →CMNDwww.ClearmindMedicine.com Creating an Alternative to Alcohol Corporate Presentation | 2024 NASDAQ: CMND FSE: CWY0 Clearmind Medicine Inc. Clearmind Medicine Inc. P a ge 2 All statements in this presentation, other than t
Clearmind Medicine Inc. is a Canadian company dedicated to creating non-alcoholic alternatives to traditional alcoholic beverages. The company is focusing on developing a patented beverage based on MEAI, a neurologically active compound that aims to provide alcohol-like sensations without the adverse effects of alcohol. The global market for low-alcohol options is thriving, with expectations of significant growth in consumer interest. Clearmind's strong management team and innovative product offerings position it well within this expanding market segment.
Read more →CMNDClearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
Clearmind Medicine Inc. has announced the submission of an international patent application for its generation 3.0 psychedelic compounds as part of its collaboration with Yissum Research Development Company. This application aims to secure intellectual property rights for novel methods in treating mental disorders. The patent, if approved, allows Clearmind to advance into the national phase for patent protection across various significant jurisdictions. The CEO expressed confidence in the role of psychedelic treatments in addressing mental health challenges and emphasized Clearmind's commitment to innovation in this field.
Read more →CMNDClearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug
Clearmind Medicine has announced a new study indicating that its compound MEAI shows promise as a novel weight loss drug. Research conducted by a team from the Hebrew University of Jerusalem indicated that MEAI significantly reduced diet-induced obesity in mice, improved metabolism, and decreased fatty liver disease. The CEO of Clearmind highlighted MEAI's potential to be a breakthrough in obesity treatment, with advantages over current marketed options. However, the announcement includes forward-looking statements, implying uncertainties in achieving the expected outcomes.
Read more →CMNDClearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research
Clearmind Medicine Inc. successfully participated in the Psychedelic Medicine – Israel 2024 conference, where it presented groundbreaking research on its compound 5-Methoxy-2-Aminoindane (MEAI). The CEO, Dr. Adi Zuloff-Shani, discussed MEAI's potential as a binge behavior regulator, and researchers from The Hebrew University of Jerusalem shared its promising effects on obesity. The conference facilitated valuable networking opportunities and enhanced awareness of Clearmind's innovative therapeutic approaches in the psychedelic medicine space.
Read more →CMNDClearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
Clearmind Medicine Inc. (CMND) has partnered with JS First Sdn. Bhd to source global manufacturers and distributors for its MEAI-based alcohol substitute beverage. This strategic engagement aims to enhance Clearmind's presence in the international non-alcoholic beverage market, building on its patented product designed to provide the same social benefits of alcohol without negative health impacts. The partnership is expected to facilitate manufacturing and distribution across multiple regions including the U.S., Europe, Africa, and Southeast Asia, capitalizing on a growing market worth over $13 billion.
Read more →CMNDClearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism
Clearmind Medicine Inc. has received Investigational New Drug (IND) approval from the FDA for its CMND-100 oral capsule aimed at treating alcohol use disorder (AUD). This approval allows the company to initiate Phase I/IIa clinical trials in the U.S., building upon existing approval in Israel. The trials will evaluate the safety, tolerability, and preliminary efficacy of CMND-100 in both healthy volunteers and AUD patients. The main active ingredient is MEAI, a non-hallucinogenic psychoactive compound thought to reduce alcohol cravings.
Read more →CMNDClearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss
Clearmind Medicine Inc. has announced the submission of a new patent application focused on treating metabolic syndrome and obesity, utilizing their MEAI compound with Palmitoylethanolamide. This effort is part of a collaboration with SciSparc Ltd. and highlights an innovative approach to addressing obesity-related health issues. The global obesity treatment market is projected to grow significantly, which could benefit the company financially. However, the success of the patent application and the actualization of these plans are subject to various uncertainties and risks.
Read more →CMNDClearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
Clearmind Medicine Inc. is set to present groundbreaking research on 5-Methoxy-2-Aminoindane (MEAI) at the Psychedelic Medicine – Israel 2024 conference, scheduled for July 28-30 in Tel Aviv. CEO Dr. Adi Zullof-Shani will discuss MEAI's potential to regulate binge behaviors and treat addiction-related disorders. Additionally, researchers from The Hebrew University of Jerusalem will share findings on MEAI’s effects on diet-induced obesity. This participation highlights Clearmind's commitment to pioneering psychedelic-derived therapeutics for major health challenges.
Read more →CMNDClearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment
Clearmind Medicine Inc. has achieved patent approval in Hong Kong for its MEAI-based treatment aimed at regulating binge behaviors. This development enhances the company's existing broad intellectual property protection, which now includes 28 patents across multiple major jurisdictions. MEAI is designed to reduce the desire for alcohol and has implications in treating Alcohol Use Disorder and obesity. Clearmind continues to seek additional patents to strengthen its position in the psychedelic therapeutics market.
Read more →CMNDClearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
Clearmind Medicine Inc. has secured exclusive global rights to innovative psychedelic compounds for the treatment of PTSD through a patent licensing agreement with Yissum Research Development Company. This partnership aims to develop and commercialize these promising compounds to address the growing market for PTSD treatment, projected to increase from $16.8 billion in 2023 to $27.37 billion by 2033. Clearmind will manage the ongoing development in compliance with regulatory guidelines, enhancing their position in a sector with limited existing treatment efficacy. The agreement also includes potential financial benefits through milestone payments and royalties on future sales.
Read more →CMNDClearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink
Clearmind Medicine Inc. has announced progress in its MEAI-based alcohol substitute beverage program, necessary for a novel-food application. The company has secured patents in the U.S., India, and Europe. With the no-low alcohol market valued over $13 billion and expected to grow, Clearmind is positioned to capitalize on this trend under the direction of seasoned industry leader Nicholas Kadysh. As a clinical-stage biotech firm, Clearmind aims to address issues like alcohol use disorder through its psychedelic-derived therapeutics.
Read more →CMNDClearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
Clearmind Medicine Inc. has made significant progress in its proprietary MEAI-based synthetic alcohol beverage, having completed most pre-clinical studies necessary for a novel-food application. The company's product aims to serve as a health-focused alternative to traditional alcohol, aligning with the growing consumer trends towards no- and low-alcohol beverages. Clearmind has obtained patents for its product in the U.S., India, and Europe, positioning itself favorably within a market estimated to be worth over $13 billion and projected to see continued growth towards 2027.
Read more →CMNDClearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment
Clearmind Medicine Inc. has announced an exclusive patent licensing agreement with Yissum Research Development Company, granting it the rights to develop and commercialize psychedelic compounds aimed at treating PTSD and other mental health conditions. This agreement comes at a time when the global PTSD treatment market is projected to grow from $16.8 billion in 2023 to $27.37 billion by 2033. The CEO of Clearmind, Dr. Adi Zullof-Shani, expressed optimism regarding the compounds' potential to address urgent mental health care needs, though the company acknowledges uncertainties related to patent approvals and regulatory processes. The licensing agreement underscores the significance of collaboration in advancing mental health therapeutics.
Read more →CMNDClearmind Applies to Cease Being a Reporting Issuer in Canada
Clearmind Medicine Inc. has announced its intention to apply for an order to cease being a reporting issuer in Canada, which will relieve it from the obligation of filing financial statements in that jurisdiction. This decision will allow Clearmind to focus on compliance with U.S. and German financial regulations instead. The company remains committed to developing novel psychedelic-derived therapeutics and holds a substantial patent portfolio to support its goals.
Read more →CMNDClearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
Clearmind Medicine Inc. has announced an exclusive licensing agreement with Yissum Research Development Company to advance the development of generation 3.0 psychedelic compounds for treating addiction and mental disorders. This agreement grants Clearmind worldwide rights to develop and commercialize products derived from a new patent-pending synthesis of these compounds. The company aims to leverage this innovation to strengthen its position in the psychedelic therapy market and address important health issues. Clearmind continues to focus on expanding its intellectual property portfolio in this rapidly evolving segment.
Read more →CMNDClearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
Clearmind Medicine Inc. has filed a patent application with the USPTO for a psychedelic-based treatment aimed at preventing and treating eating disorders. This application covers the use of 3-methylmethcathinone (3-MMC) either alone or in combination with Palmitoylethanolamide (PEA). The company intends to position itself as a leader in the weight loss sector, which is projected to experience significant growth in the coming years. The patent application underscores Clearmind's commitment to developing innovative therapeutics for major health issues, although it acknowledges the uncertainties associated with patent approval and market success.
Read more →CMNDClearmind Medicine CEO Issues Letter to Shareholders
Clearmind Medicine Inc. announced significant advancements in its efforts to develop CMND-100, a novel treatment for alcohol use disorder. The Israeli Ministry of Health has approved the Phase I/IIa clinical trial for this compound, which aims to effectively address binge drinking without the hallucinatory effects of existing treatments. The company highlighted its progress over the past year, including forming partnerships for clinical trial support and achieving pre-clinical success in related health issues. Clearmind expressed optimism about future achievements that could enhance shareholder value.
Read more →CMNDClearmind Medicine Announces International Patent Application for Preventing and Treating Depression
Clearmind Medicine Inc. has submitted its tenth international patent application for a novel treatment aimed at preventing and treating depression. This patent, developed in collaboration with SciSparc Ltd., involves a proprietary composition combining Clearmind's MEAI compound with Palmitoylethanolamide (PEA). The application aims to address the growing market for depression treatments, which is expected to nearly double by 2034. Clearmind's CEO highlights the lack of innovation in current antidepressants and expresses confidence in the potential of their psychedelic-derived therapies.
Read more →CMNDClearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
Clearmind Medicine has obtained approval from the Israeli Ministry of Health to begin a phase I/IIa clinical trial of its CMND-100 oral capsule for alcohol use disorder. The trial will be conducted at multiple centers, including sites in the U.S. and Israel, and is designed to assess the safety, tolerability, and preliminary efficacy of the treatment. CMND-100, which contains the psychoactive molecule MEAI, is expected to provide new options for individuals struggling with alcohol addiction. The approval marks an important milestone for Clearmind as it moves into clinical-stage development.
Read more →CMNDClearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
Clearmind Medicine Inc. has received approval for a voluntary delisting of its common shares from the Canadian Securities Exchange (CSE), effective March 14, 2024. The company cites insufficient trading volume on the CSE to justify the costs of a dual listing. The delisting is expected to concentrate trading on NASDAQ, which Clearmind believes will improve liquidity and shareholder value. Shareholders will still be able to trade shares on NASDAQ, ensuring continued access to the market.
Read more →CMNDClearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
Clearmind Medicine Inc. has submitted three additional patent applications for novel psychedelic compounds, including MDMA, Ibogaine, and Ketamine, to enhance its intellectual property portfolio. This move is part of an ongoing collaboration with SciSparc Ltd., aimed at developing therapies for central nervous system disorders. Currently, Clearmind boasts a total of 27 granted patents and 24 pending applications across 15 families of patents, demonstrating its commitment to leading in the psychedelic therapeutic space.
Read more →CMNDClearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
Clearmind Medicine Inc. has received approval from the Israeli Ministry of Health to begin a Phase I/IIa clinical trial for its psychedelic drug CMND-100, aimed at treating alcohol use disorder (AUD). This study will explore the safety and pharmacokinetics of CMND-100 in both healthy volunteers and AUD patients. The drug's active component, MEAI, is a non-hallucinogenic molecule that may help reduce alcohol cravings. The trial will be conducted at multiple sites, including prominent medical institutions in Israel and the U.S.
Read more →CMNDClearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
Clearmind Medicine Inc. has announced the submission of three international patent applications under the Patent Cooperation Treaty (PCT) as part of its collaboration with SciSparc Ltd. These applications are designed to protect proprietary combinations of psychedelic compounds such as LSD and psilocybin. The submission enhances Clearmind’s intellectual property portfolio, which currently comprises 27 granted patents and 24 pending applications across multiple jurisdictions. The company aims to develop novel psychedelic-derived therapeutics targeting major health issues, including alcohol use disorder.
Read more →CMNDClearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China
Clearmind Medicine Inc. has received patent approval from the China National Intellectual Property Administration for its psychedelic-based treatment targeting binge behaviors. This approval not only solidifies the company's patent protection for its flagship molecule, MEAI, but also enhances its comprehensive intellectual property portfolio in the psychedelic sector. The MEAI molecule is reported to effectively reduce the desire for alcohol, presenting potential therapeutic benefits for individuals struggling with alcohol use and binge drinking disorders. Clearmind aims to further its development of innovative psychedelic-derived treatments in the healthcare market.
Read more →CMNDClearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center
Clearmind Medicine Inc. has announced a long-term licensing agreement with BIRAD, a research subsidiary of Bar-Ilan University, for the use of a joint patent aimed at treating cocaine addiction. This alliance follows positive outcomes from pre-clinical trials demonstrating the effectiveness of Clearmind's psychedelic compound, MEAI, in reducing craving for cocaine. Clearmind CEO, Dr. Adi Zuloff-Shani, emphasized the potential for MEAI to transform addiction treatment and improve outcomes for millions globally. This agreement reinforces Clearmind's commitment to pioneering innovative treatments for addiction using psychedelic compounds.
Read more →CMNDClearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement
Clearmind Medicine Inc. has completed a $2.4 million financing round through a registered direct offering and a concurrent private placement. The transactions involved the sale of 1.5 million Common and Pre-Funded Units, including warrants for each unit sold. The proceeds will be utilized for general corporate purposes and working capital. These offerings reflect the company’s continued commitment to developing psychedelic-derived therapeutics aimed at addressing under-treated health issues.
Read more →CMNDClearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement
Clearmind Medicine Inc. has announced a $2.4 million fundraising through a registered direct offering and private placement. The company will sell Common Shares and pre-funded warrants to institutional investors, with expected proceeds aiding in general corporate purposes and working capital. The transactions are set to close on or about January 16, 2024, contingent on closing conditions. This move reflects Clearmind's commitment to developing innovative psychedelic-derived therapies for under-treated health problems.
Read more →CMNDClearmind Medicine Completed Type A Meeting with the FDA
Clearmind Medicine Inc. has successfully completed a Type A meeting with the U.S. FDA regarding its CMND-100 compound aimed at treating Alcohol Use Disorder. The meeting was described as informative and productive, aligning on the content for the IND resubmission. CMND-100 leverages the psychoactive properties of MEAI to potentially address gaps in current treatments for AUD. The company aims to advance its therapeutic development focused on psychedelic-derived solutions to significant health issues.
Read more →CMNDClearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments
Clearmind Medicine Inc. and SciSparc Ltd. have successfully collaborated throughout 2023, culminating in the filing of six provisional patent applications for novel combinations of psychedelics. The collaboration aims to enhance the therapeutic availability of psychedelic-derived treatments for mental health disorders. Clearmind's extensive intellectual property portfolio has bolstered their position in the psychedelic space, with various patents filed and granted internationally. However, the future of these developments remains uncertain due to potential challenges in the patent approval process.
Read more →CMNDClearmind Medicine Announces It Is In Compliance with All Applicable Nasdaq Listing Standards
Clearmind Medicine Inc. announced it has regained compliance with Nasdaq listing standards after receiving formal notification from Nasdaq. The company maintained a minimum bid price greater than $1.00 for ten consecutive business days, resolving a previous bid price deficiency. As a result, a scheduled hearing regarding potential suspension has been canceled, ensuring the company's shares continue trading on Nasdaq. Clearmind focuses on developing psychedelic-derived therapeutics addressing under-treated health issues.
Read more →CMNDClearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment
Clearmind Medicine Inc. announced positive results from its trials for a treatment targeting cocaine addiction using its psychedelic molecule, MEAI. This innovative approach aims to address a significant global health issue, as current treatment options are lacking. The trial, led by Professor Gal Yadid, demonstrated the efficacy of MEAI, potentially revolutionizing addiction treatment protocols. Clearmind's commitment to developing psychedelic-derived therapeutics is underscored by a recent patent application related to this treatment.
Read more →CMNDClearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment
Clearmind Medicine Inc. announced positive outcomes from its pre-clinical trial of a novel weight loss and metabolic disorder treatment. The study, which focused on a combination of Clearmind's MEAI and SciSparc's PEA, demonstrated promising effects on critical metabolic parameters such as fat oxidation and appetite suppression. Results indicated increased energy expenditure without adverse effects on animal viability. The findings suggest the potential for a safer, more effective alternative to current weight loss medications.
Read more →CMNDClearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures
Clearmind Medicine Inc. will participate in a virtual event discussing the psychedelic landscape, featuring notable figures such as CEO Dr. Adi Zuloff-Shani and MAPS founder Rick Doblin. The event, part of The Psychedelic Association of Canada's series, aims to explore both traditional and novel psychedelics, promising to shed light on current clinical studies and psychedelic therapies. Scheduled for November 29, 2023, the event aims to provide insights into the therapeutic potential of psychedelics in treating under-served health issues.
Read more →CMNDClearmind Medicine Announces 1-for-30 Reverse Share Split
Clearmind Medicine Inc. has announced a 1-for-30 reverse share split aimed at regaining compliance with Nasdaq's Minimum Bid Price Rule, effective November 28, 2023. This decision was approved by shareholders and the board of directors during a recent general meeting. The company's total issued and outstanding shares will decrease significantly from approximately 18.2 million to about 607,381 shares. While the authorized share capital remains unchanged, there are potential risks associated with the company's compliance and market perception following this action.
Read more →CMNDClearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance
Clearmind Medicine Inc. has received a delisting notice from Nasdaq due to not maintaining the minimum bid price of $1.00 per share for thirty consecutive business days. The company plans to appeal this determination and has already received shareholder approval for a reverse stock split as part of its strategy to regain compliance. A hearing request will stay the suspension of the company's securities while the panel reviews the situation. The company aims to update shareholders about its compliance status in the near future.
Read more →CMNDClearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance As part of the Company's plan for recompliance, the Company's shareholders approved a reverse stock split on
Clearmind Medicine Inc. received a delisting notice from Nasdaq due to not maintaining a minimum bid price for thirty consecutive days. In response, the company plans to appeal the decision while implementing a reverse stock split approved by shareholders. This action aims to regain compliance with Nasdaq regulations and maintain the listing of its securities. Additional details regarding the reverse stock split are expected to be released soon.
Read more →CMNDClearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities
Clearmind Medicine Inc. has entered a Clinical Trial Agreement with Johns Hopkins University School of Medicine and Yale University to conduct its Phase I/IIa clinical trial for CMND-100, a treatment for Alcohol Use Disorder. This multinational study will assess the drug's safety, tolerability, and pharmacokinetics in healthy volunteers and individuals with AUD. It represents a significant milestone in exploring psychedelic-based therapies for treating addiction, a commonly faced health problem.
Read more →CMNDClearmind Medicine to Present at the 8th Annual Dawson James Conference on October 12th
Clearmind Medicine Inc. will present at the 8th Annual Dawson James Conference on October 12, 2023. Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, will deliver a presentation and participate in one-on-one meetings with investors at the event located in Jupiter, Florida. The conference is known for facilitating capital raising for small and microcap companies in various sectors, including healthcare. Clearmind focuses on developing innovative psychedelic-derived therapeutics aimed at addressing major under-treated health problems, such as alcohol use disorder.
Read more →CMNDClearmind Medicine Closes US$2.25 Million Public Offering
Clearmind Medicine Inc. announced the closure of its U.S.-only public offering, which raised around US$2.25 million in gross proceeds. This offering involved 7,500,000 common shares combined with warrants, with proceeds earmarked for general corporate purposes including R&D and potential acquisitions. Notably, the offering was exclusively for U.S. investors, excluding Canadian residents. Clearmind aims to leverage these funds to advance its development of psychedelic-derived therapeutics.
Read more →CMNDClearmind Medicine Announces Pricing of US$2.25 Million Public Offering
Clearmind Medicine Inc. has announced the pricing of a public offering aimed at raising approximately $2.25 million, which is set to close on September 18, 2023. The offering will consist of 7.5 million common shares in conjunction with warrants. The funds raised are intended for general corporate purposes, including the research and development of novel psychedelic-derived therapeutics. The offerings are exclusive to the U.S. market, and details regarding the terms have been filed with the SEC.
Read more →CMNDClearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder
Clearmind Medicine has entered into a Clinical Trial Agreement with Johns Hopkins University to conduct a Phase I/IIa clinical trial of its CMND-100 for Alcohol Use Disorder. This marks Clearmind's first human clinical trial and will evaluate the drug's tolerability, safety, and pharmacokinetics. The study will involve daily administration of CMND-100 over ten days, assessing its effectiveness in reducing drinking patterns and cravings among participants. The inclusion of JHU alongside Yale increases the study's prestige and validation within the psychedelics research community.
Read more →CMNDClearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company
Clearmind Medicine Inc. has announced a collaboration with CTS Ltd., a leading pharmaceutical and consumer products company, to advance the development of psychedelic-derived therapeutics. This partnership enables Clearmind to access CTS's state-of-the-art facilities and industry expertise, which will bolster its research capabilities. The collaboration is seen as a significant milestone in the growing field of psychedelic therapies, aiming to improve treatment options for mental health conditions. Clearmind's CEO expressed optimism regarding the innovative potential of this partnership.
Read more →CMNDClearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio
Clearmind Medicine has filed a provisional patent application with the USPTO for the treatment of Dyskinesia, utilizing the psychedelic molecule 3-Methylmethcathinone (3-MMC). This move aims to expand the company's intellectual property portfolio, which already includes 30 patents and applications in various jurisdictions. The application also includes protection for a unique combination of 3-MMC and SciSparc's Palmitoylethanolamide. Clearmind's CEO emphasized the potential of their targeted treatments to assist patients facing debilitating movement disorders.
Read more →CMNDClearmind Medicine Announces Share-Based Payment for the Company's Consultants
Clearmind Medicine Inc. announced the issuance of 17,899 common shares and restricted stock units to consultants as payment, totaling $15,000. The payments are part of the company's ongoing strategy to compensate advisors while reinforcing its commitment to psychedelic-based therapeutics. Clearmind focuses on developing solutions for under-treated health problems, such as alcohol use disorder, and holds a portfolio of fourteen patent families. The company aims to expand its intellectual property while seeking regulatory approval for its compounds.
Read more →CMNDDr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board Tel Aviv, Israel/Vancouver, Canada
Clearmind Medicine Inc. announced the appointment of Dr. Fatima Cody Stanford to its Scientific Advisory Board. Dr. Stanford, an Associate Professor at Harvard Medical School, brings significant expertise in obesity treatment, crucial for advancing Clearmind's mission to develop psychedelic-based therapies for metabolic issues. The announcement follows promising pre-clinical results showing MEAI's potential benefits in obesity treatment. Clearmind seeks to revolutionize therapeutic approaches in this area, emphasizing innovative solutions for major health challenges.
Read more →CMNDClearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
Clearmind Medicine Inc. is collaborating with SciSparc Ltd. to conduct a study at the Hebrew University of Jerusalem, evaluating a combination treatment for obesity and metabolic syndrome that incorporates Clearmind's MEAI and SciSparc's PEA. The study aims to build on previous promising pre-clinical results showing significant improvements in metabolic profiles and weight loss. Clearmind's CEO expressed optimism about the synergistic effects of the treatment, highlighting its potential benefits for compulsive eating behaviors.
Read more →CMNDClearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
Clearmind Medicine Inc. will host a virtual investor conference titled "Psychedelics for Obesity" on June 12, showcasing positive pre-clinical results for its drug candidate MEAI in addressing obesity. The presentation will include insights from Professor Joseph Tam on the efficacy and challenges related to obesity treatment. CEO Dr. Adi Zuloff-Shani will discuss Clearmind's achievements and future goals during the event. The company focuses on developing psychedelic-derived therapeutics and holds a robust intellectual property portfolio.
Read more →CMNDClearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder
Clearmind Medicine has announced the selection of Yale School of Medicine as the first U.S. site for its Phase I/IIa clinical trial evaluating the efficacy of CMND-100 in treating alcohol use disorder. Led by Dr. Anahita Bassir Nia, the trial aims to assess tolerability, safety, and pharmacokinetics of the compound. Clearmind's confidence in CMND-100 is bolstered by previous pre-clinical studies suggesting its therapeutic potential. The trial's primary objective includes determining dose tolerability while evaluating its effectiveness in reducing alcohol cravings among participants.
Read more →CMNDClearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder
Clearmind Medicine Inc. has received Ethics Committee approval for its Phase I/II clinical trial of CMND-100, a treatment for alcohol use disorder (AUD), at Israel's IMCA center. The trial aims to determine the safety and pharmacokinetics of CMND-100 and evaluate its efficacy in reducing alcohol cravings among patients with moderate-to-severe AUD. The study, led by Prof. Mark Weiser, will involve healthy volunteers as well as AUD subjects. Clearmind plans to expand the trial to additional sites in the U.S.
Read more →CMNDClearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants
Clearmind Medicine Inc. has announced the retention of Crescendo Communications LLC to enhance its investor relations and capital markets communications. The company also reported the issuance of 90,146 shares and 2,241 warrants as part of previously disclosed agreements. Clearmind focuses on developing psychedelic-derived therapeutics to address untreated health problems, notably alcohol use disorder. This strategic move aims to fortify the company's position in the biotech sector.
Read more →CMNDClearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam
Clearmind Medicine Inc. has appointed Professor Joseph Tam to its Scientific Advisory Board, enhancing its expertise in obesity and metabolic disorders. Professor Tam, a distinguished academic from Hebrew University of Jerusalem, brings significant research credentials, particularly in cannabinoid research. Clearmind's CEO expressed optimism regarding the potential of their psychedelic-derived therapeutics, supported by promising preclinical data. This collaboration aims to address major health challenges related to addiction and metabolic conditions.
Read more →CMNDClearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial
Clearmind Medicine Inc. has announced a clinical supply agreement with IMP Clinical Supply Services for its upcoming trial of the drug candidate CMND-100. This agreement is crucial for managing the global supply chain of the drug, ensuring compliance with industry standards. The clinical trial is set to begin in Q2 2023 in the U.S. and Israel, focusing on the safety and efficacy of CMND-100 in treating Alcohol Use Disorder. The market for treating Alcohol Use Disorder is projected to grow significantly in the coming years, highlighting the potential impact of Clearmind's research.
Read more →CMNDClearmind Medicine Forms a Data and Safety Monitoring Board to Oversee its First-in-Human Clinical Trial
Clearmind Medicine Inc. has established a Data and Safety Monitoring Board (DSMB) to oversee its first-in-human clinical trial focused on treating Alcohol Use Disorder. The DSMB comprises specialists in internal medicine, psychiatry, and biostatistics, tasked with ensuring participant safety and data integrity. The formation of this committee aligns with the company's commitment to prioritize patient safety during its clinical endeavors. Clearmind aims to develop psychedelic-derived therapeutics to address major health issues, emphasizing its novel approach in the pharmaceutical landscape.
Read more →CMNDClearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
Clearmind Medicine Inc. has filed a patent application with the USPTO for its unique combination of MEAI and SciSparc's Cannamide™ aimed at treating depression. This initiative is part of a collaborative effort with SciSparc and contributes to Clearmind's extensive intellectual property portfolio. The company currently holds 24 patents across 14 families, emphasizing a focus on developing psychedelic-derived therapeutics for several health issues. However, there are inherent risks associated with the patent process and potential discrepancies between projected and actual results.
Read more →CMNDClearmind Medicine Engages Experienced Contract Research Organization to Support its First-in-Human Clinical Trial
Clearmind Medicine Inc. has engaged a contract research organization to support its first-in-human clinical trial for the proprietary drug candidate CMND-100, aimed at treating Alcohol Use Disorder. The trial preparations are progressing, signaling an advanced stage of development. The CEO highlighted the importance of this trial in addressing alcoholism, which affects many individuals. Clearmind is focused on developing novel psychedelic-derived therapeutics as regulated medicines.
Read more →CMNDClearmind Medicine Closes US$3.5 Million Public Offering
Clearmind Medicine Inc. has announced the successful closing of its US-only public offering, raising approximately US$3.5 million. This offering included the sale of common shares and warrants, which are intended to finance general corporate operations, research and development, and potential future acquisitions. The company is focused on developing psychedelic-derived therapeutics for under-treated health issues, including alcohol use disorder, and plans to utilize the proceeds to further advance its clinical and pre-clinical testing.
Read more →CMNDClearmind Medicine Announces Pricing of US$3.5 Million Public Offering
Clearmind Medicine Inc. has announced a public offering aimed at raising approximately US$3.5 million through the sale of 4,505,718 common shares and warrants. The proceeds from this offering are intended for general corporate purposes, including research and development. This offering reflects the company's ambitions to advance its psychedelic-derived therapeutics aimed at addressing under-treated health issues.
Read more →CMNDClearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder
Clearmind Medicine Inc. has submitted an IND application to the FDA for its CMND-100 treatment aimed at alcohol use disorder. The company plans to initiate Phase I/IIa clinical trials in Q2 2023, pending regulatory approval. The active ingredient, MEAI, is a novel psychoactive molecule that may reduce the desire for alcohol while producing euphoric effects. This initiative highlights Clearmind's commitment to finding new solutions for alcohol use disorder, which affects millions globally.
Read more →CMNDClearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory Board
Clearmind Medicine Inc. has appointed Professor Henry R. Kranzler, M.D., to its Scientific Advisory Board. Professor Kranzler is a renowned expert in addiction medicine and serves as the Director of the Center for Studies of Addiction at the University of Pennsylvania. His extensive background in research, particularly in the genetics and pharmacology of substance dependence, is expected to contribute significantly to Clearmind's focus on developing novel psychedelic-derived therapeutics for addiction disorders. CEO Dr. Adi Zuloff-Shani expressed excitement over Kranzler's contributions to the company’s mission.
Read more →CMNDIsrael-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds The company submitted three provisional patent applications with the United States Patent and
Clearmind Medicine Inc. has announced the filing of three provisional patent applications with the United States Patent and Trademark Office. These applications protect unique combinations of psychedelic compounds, including MDMA, Ibogaine, and Ketamine, with SciSparc's CannAmide. The initiative aligns with Clearmind's strategy to expand its intellectual property and develop innovative treatments for mental health disorders. The company's CEO expressed optimism about the potential to address unmet patient needs through these novel compounds.
Read more →CMNDIsrael-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US The applications for novel psychedelic-based combinations, developed with SciSparc, are based on monotherapy
Clearmind Medicine Inc. has announced the filing of three provisional patent applications with the USPTO to develop novel psychedelic-based combinations in collaboration with SciSparc Ltd. The patents focus on proprietary combinations of substances like LSD, psilocybin, and DMT alongside SciSparc's CannAmide. This move is part of Clearmind's strategy to enhance treatment options for mental health disorders, aimed at improving efficacy, safety, and cost-effectiveness. The company currently holds a strong intellectual property portfolio in this emerging therapeutic space.
Read more →CMNDIsraeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity The conference will stream live on Tuesday, February 28, at 8:30 AM EST Tel Aviv, Israel / Vancouver, Canada
Clearmind Medicine Inc. is hosting a virtual investor conference on February 28, 2023, focusing on the use of psychedelics in treating obesity. The conference will feature presentations from key figures, including Professor Joseph Tam, who will discuss encouraging pre-clinical results of the drug candidate MEAI. Clearmind is dedicated to developing therapeutic solutions for various health issues using psychedelic compounds, emphasizing its commitment to addressing significant health concerns.
Read more →CMNDCLEARMIND MEDICINE INC. Consolidated Financial Statements (Expressed in Canadian Dollars) F- 1 CLEARMIND MEDICINE INC. Index of Financial Statements As of
Clearmind Medicine Inc. has released its consolidated financial statements for the periods ending October 31, 2022, and October 31, 2021. The audit report indicates that while the financial statements present fairly in all material respects, the company faces significant uncertainties regarding its ability to continue as a going concern due to accumulated losses and negative cash flow. The independent auditors have expressed their opinion without modification but highlighted these uncertainties in the financial report.
Read more →CMNDIsraeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound Tel Aviv, Israel / Vancouver, Canada
Clearmind Medicine Inc. reported positive pre-clinical results regarding its compound 2-Fluorodeschloroketamine (2-FDCK) in treating Major Depression. The trial revealed that 2-FDCK exhibited superior effects on depressive-like behavior in animal models compared to traditional Ketamine. These results are seen as a potential advancement in addressing treatment-resistant depression, with Clearmind emphasizing their commitment to developing innovative psychedelic-derived therapeutics.
Read more →CMNDHebrew University' Yissum and Israeli Biotech Clearmind Medicine's Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023 Isranalytica 2023, the Annual meeting of the
Clearmind Medicine presented its promising drug candidate, MEAI, for obesity treatment at Isranalytica 2023, led by Professor Joseph Tam. His presentation highlighted pre-clinical results indicating MEAI's efficacy in treating obesity and metabolic syndrome. This annual conference offered an important platform for Clearmind to increase awareness of its innovative psychedelic-derived therapies among professionals in the medical field. The collaboration with the Hebrew University boosts Clearmind's research initiatives and ongoing development in this area.
Read more →CMNDIsrael-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem's Tech Transfer Company, Yissum The two drug-discovery projects for novel, next generation, innovative, patentable ps
Clearmind Medicine Inc., a biotechnology company based in Israel, has successfully completed two R&D projects in collaboration with Yissum of the Hebrew University of Jerusalem. These projects focused on developing innovative psychedelic compounds aimed at addressing significant health challenges. The results are expected to enhance Clearmind's intellectual property portfolio and advance multiple promising drug candidates for future patent applications. The work showcases fruitful collaboration with leading academic institutions, aligning with the company's mission to advance psychedelic drug discovery.
Read more →CMNDIsrael-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment The results of pre-clinical in-vivo research studies suggested that Clearmind's d
Clearmind Medicine Inc. announced encouraging pre-clinical results from its studies on MEAI, a drug candidate aimed at treating cocaine addiction. The research indicates that MEAI can effectively decrease cocaine cravings while maintaining the natural reward process, a significant finding in addiction therapy. Led by Professor Gal Yadid, the studies suggest that MEAI may become the first dedicated treatment for cocaine addiction, addressing a major health concern that currently lacks effective solutions. Further research will be necessary to better understand the drug's efficacy and its potential applications.
Read more →CMNDIsrael-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial Tel Aviv, Israel / Vancouver, Canada
Clearmind Medicine Inc. has successfully manufactured its drug candidate CMND-100, which is set to enter its first in-human clinical trial aimed at treating Alcohol Use Disorder (AUD). The drug's production was completed under Good Manufacturing Process (GMP) conditions, ensuring compliance with FDA requirements. Clearmind's CEO highlighted the achievement as a significant milestone, following positive pre-clinical results for the drug's efficacy. The company continues to prepare for the clinical program that will evaluate this innovative treatment.
Read more →CMNDIsrael-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial In a series of pre-clinical trials, Clearmind's drug candidate MEAI significantly reduced body weight, improv
Clearmind Medicine has reported promising pre-clinical trial results for its psychedelic-derived candidate MEAI, which showed significant efficacy in reducing body weight and improving metabolic health. Conducted in collaboration with the Hebrew University of Jerusalem, the study demonstrated that MEAI-treated rodents experienced a 20% reduction in body weight and improved metabolic parameters without adverse effects on motivation and well-being. These findings highlight the potential of MEAI for treating obesity and related health conditions, positioning Clearmind favorably in a rapidly growing obesity treatment market.
Read more →CMNDIsrael-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder Company engaged a leading clinical center in Israel and intends to conduct its first- in- human trial in
Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder engaged a leading clinical center in Israel and intends to conduct its first- in- human trial in the United States as well Aviv, Israel / Vancouver, Canada, Dec. 28, 2022 (GLO
Read more →CMNDIsrael- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based Alcohol Substitute U . S . Patent and Trademark Office extends protection of Clearmind's proprietary MEAI and expands its potential market Tel Av
Israel- Based Clearmind Medicine Granted U.S. Patent for Psychedelic-Based U.S. Patent and Trademark Office extends protection of Clearmind's proprietary MEAI and expands its potential market Tel Aviv, Israel / Vancouver, Canada, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Clearmind Me
Read more →CMNDIsraeli Based Biotech Company Clearmind Medicine Inc's CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders Tel Aviv, Israel / Vancouver, Canada
Israeli Based Biotech Company Clearmind Medicine Inc's CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders Tel Aviv, Israel / Vancouver, Canada, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND) (FSE: CWY) ("Clearmind or the "Company ), a biot
Read more →CMNDIsraeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100 The MEAI-based proprietary compound is aimed at treating Alcohol Use Disorder Tel Aviv, Israel / Vancouver, Canada
Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100 The MEAI-based proprietary compound is aimed at treating Alcohol Tel Aviv, Israel / Vancouver, Canada, December 13, 2022 -- Clearmind Medicine Inc. (Nasdaq,CSE: CMND), (FSE: CWY) ("Clearmind"
Read more →CMNDIsraeli Biotech Clearmind Medicine Appoints ex-Red Bull Executive Special Advisor for Developing MEAI as Alcohol Substitute Nicholas Kadysh, a former Red Bull Canada and Juul Labs Canada executive, is an expert on regula
Biotech Clearmind Medicine Appoints ex-Red Bull Executive Special Advisor for Developing MEAI as Alcohol Substitute Nicholas Kadysh, a former Red Bull Canada and Juul Labs Canada executive, is an expert on regulatory issues 9, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc.
Read more →CMNDCLEARMIND MEDICINE INC. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the annual and special meeting (the " Meeting ") of the holders of the common shares (collectively, the " Sharehold
CLEARMIND MEDICINE INC. NOTICE OF ANNUAL AND SPECIAL MEETING GIVEN that the annual and special meeting (the "Meeting") of the holders of the common shares (collectively, the "Shareholders" or individually, a "Shareholder") of Clearmind Medicine Inc. (the "Company" or the "Cor
Read more →CMNDClearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial
VANCOUVER, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problem
Read more →CMNDClearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market
VANCOUVER, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq and CSE: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, t
Read more →CMNDClearmind Medicine Announces Pricing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market
VANCOUVER, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq and CSE: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, t
Read more →CMNDClearmind Medicine Featured in "Psychedelics Tonight," Streaming on ALTRD.TV
The first episode, "Psychedelic Novelty - Before it was Cool," introduces the company's proprietary molecule MEAI VANCOUVER, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company fo
Read more →CMNDClearmind Announces Notice of Proposed Stock Consolidation
VANCOUVER, Sept. 25, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health pr
Read more →CMNDClearmind Applies for Patent to Treat Obesity and Metabolic Syndrome
Patent Application, Based on Research at the Hebrew University, is Latest Result of Ongoing Collaboration with SciSparc Ltd. VANCOUVER, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the "Company"), a biotec
Read more →CMNDClearmind Medicine Announces Share-Based Payment for one of the Company's Consultants
VANCOUVER, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health pr
Read more →CMNDClearmind Medicine Announces Additional Positive Pre-Clinical Results for its Cocaine Addiction Treatment
The dedicated treatment indicated a significant decrease in cocaine craving in a sub- group that received Clearmind's MEAI VANCOUVER, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the "company"), a biotech c
Read more →CMNDClearmind Medicine Appoints New Chief Financial Officer
VANCOUVER, June 15, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problem
Read more →CMNDClearmind Medicine Announces Positive Pre-Clinical Results for Cocaine Addiction Treatment
The dedicated treatment demonstrated a significant decrease in preference for an area associated with cocaine VANCOUVER, June 07, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focuse
Read more →CMNDClearmind Medicine and SciSparc Collaboration Yields Another Patent Application for Cocaine Addiction Treatment
No dedicated treatment currently available for cocaine addiction VANCOUVER, June 02, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedel
Read more →CMNDClearmind Medicine Granted Patent Approval for Psychedelic- Based Alcohol Substitute in India
The patent was granted by India’s Office of the Controller-General of Patents, Designs and Trademarks VANCOUVER, June 01, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the "Company"), a biotech company focused on discove
Read more →CMNDClearmind Announces Successful Pre-IND Meeting with U.S. FDA for CMND-100 for Alcohol Use Disorder
Clearmind aims to initiate clinical trials with CMND-100 by year’s end VANCOUVER, May 26, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF,FSE: CWY0) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psych
Read more →CMNDClearmind Medicine and SciSparc Collaboration Yields Positive Results for its Psychedelic Combination Treatment
Pre-clinical trial based on the proprietary combination demonstrates high safety profile in addition to a significant suppressive effect on alcohol consumption Vancouver, May 24, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind
Read more →CMNDClearmind Medicine Announces Successful Pre-Clinical Results in MEAI Treatment for Alcohol Consumption
Pre-clinical trial demonstrated high safety profile in addition to a significant suppressive effect on alcohol consumption VANCOUVER, May 19, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the “Company”, a biotech company
Read more →CMNDClearmind Announces Pre-IND Meeting Date with FDA
Clearmind aims to initiate clinical trials with CMND-100 by year’s end Vancouver, May 13, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psyc
Read more →CMNDClearmind Medicine Inc. and SciSparc Ltd., Collaboration Yields New Provisional Patent Application for Psychedelic Combination Treatment for Binge Behaviors
Pre-clinical trials based on proprietary combination demonstrate significant suppressive effect on alcohol consumption TORONTO, May 10, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the "Company"), a biotech company foc
Read more →CMNDClearmind Strengthens its Scientific Advisory Board With Substance Abuse and Mental Health Professionals
Prof. Schütz’ main research interests focus on clinical interventions and health service in substance use disorders and mental health diagnoses; Prof. Weiser specializes in psychiatric disorders such as substance abuse and depression. TORONTO, May 09, 2022 (GLOBE NEWSWIRE) -- C
Read more →CMNDClearmind Medicine to Partner with Microdose for Psychedelic Capital: Mar 2022 Today, Thursday, March 24th
TORONTO, March 24, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread
Read more →CMNDClearmind Medicine Announces Positive Results on CMND-100 trials
Two pre-clinical trials based on MEAI exhibited a significant suppressive effect on alcohol consumption in mice TORONTO, March 17, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the "Company") today announced promising r
Read more →CMNDClearmind Medicine, SciSparc Launch a Psychedelic Pharma Collaboration
The companies have begun the Collaboration with a joint pre-clinical study and are expecting its results potentially to deepen the Collaboration between the parties. TORONTO, March 08, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Cle
Read more →CMNDClearmind Medicine to Host a "Psychedelics for Alcoholism" Event for Investors on February 23
Market analyst Marissa Wright discusses the psychedelics market with a focus on psychedelic treatments for alcohol use disorder TORONTO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the "Company"), a biotech c
Read more →CMNDClearmind Medicine announces Share-Based Compensation Plan
TORONTO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread
Read more →CMNDClearmind Medicine Secures CAD$1.6 Million in Private Placement
TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread
Read more →CMNDClearmind Medicine Now Fully Eligible for Settlement through the Depository Trust Company (“DTC”)
Picture1TORONTO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve wid
Read more →CMNDClearmind Medicine Engages the Independent Trading Group as a Market Maker and Thunder11 as a PR Agency
TORONTO, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread
Read more →CMNDClearmind Medicine to Host “Psychedelic for Alcoholism: From Molecule to Medicine” Virtual Event on January 26
Clearmind’s Management Team Will Explain the Regulatory Process Required for Clearmind’s Patented MEAI Molecule to Become an FDA Approved Medicine for Treating Alcohol Use Disorder and Binge Drinking TORONTO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND,
Read more →CMNDClearmind Medicine's VP of Business Development Presented at The Canadian Psychedelics Association Event
The CPA's Panel for physicians and medical professionals addressed "New Psychedelic Substances" TORONTO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focus
Read more →CMNDClearmind Medicine Strengthens Presence in North America with New Senior Appointments
TORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread
Read more →CMNDClearmind Medicine Establishes Third R&D Partnership With the Hebrew University
TORONTO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the “Company”), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread
Read more →CMNDClearmind Medicine Launches Study for Binge Eating with The Hebrew University Using its Proprietary MEAI Compound
Focus on the discovery and development of novel therapeutic strategies to treat obesity and its related metabolic disorders TORONTO, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF), (“Clearmind” or the “Company”), a psychedelic m
Read more →CMNDClearmind Medicine to Pursue Dual Listing on Nasdaq
Toronto, Ontario, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF), (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve
Read more →CMNDClearmind Signs Development and Supply Agreement to Produce Its Drug Candidate MEAI Psychedelic Molecule With Aragen Life Sciences
TORONTO, Ontario, Oct. 26, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0), (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solv
Read more →CMNDClearmind Medicine Appoints Distinguished Addiction Experts Professor Wim van den Brink and Professor Gabriele Fischer to Its Scientific Advisory Board
TORONTO, Ontario, Oct. 14, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to sol
Read more →CMNDClearmind Medicine Files Provisional Patent Application Related to Methods of Drug-Assisted Psychotherapy
TORONTO, Ontario, Oct. 13, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to sol
Read more →CMNDClearmind Medicine Partners With Clinipace to Commence Processes Towards FDA Approval
Toronto, Ontario, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0), (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to sol
Read more →CMNDClearmind Medicine to Host ‘Psychedelics for Alcoholism‘ Virtual Educational Event on October 20
TORONTO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and unde
Read more →CMNDClearmind Medicine Partners with The Hebrew University to Develop Novel Psychedelic Drug
TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and un
Read more →CMNDClearmind Issues Shareholder Letter
Toronto, July 20, 2021 (GLOBE NEWSWIRE) -- via InvestorWire-- Clearmind Medicine Inc. (CSE: CMND) ("Clearmind" or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and unde
Read more →Competitive Position
How CMND ranks across every disease it competes inCompetitive Position is a premium feature
See how CMND ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial